News coverage about Celldex Therapeutics (NASDAQ:CLDX) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Celldex Therapeutics earned a news sentiment score of 0.22 on Accern’s scale. Accern also gave news coverage about the biopharmaceutical company an impact score of 45.2710890184729 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
These are some of the news articles that may have effected Accern Sentiment’s scoring:
- HC Wainwright Analysts Give Celldex Therapeutics (CLDX) a $10.00 Price Target (americanbankingnews.com)
- Implied Volatility Surging for Celldex Therapeutics (CLDX) Stock Options (zacks.com)
- Notable Investor’s Alert – Deutsche Bank Aktiengesellschaft, NYSE: DB), Celldex Therapeutics, Inc., (NASDAQ: CLDX) (dailynysenews.com)
- Celldex Therapeutics, Inc. (CLDX) Reached 52 Week Low on Apr, 6 (thecasualsmart.com)
- $2.03 Million in Sales Expected for Celldex Therapeutics, Inc. (CLDX) This Quarter (americanbankingnews.com)
CLDX has been the subject of a number of recent analyst reports. BidaskClub upgraded shares of Celldex Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. HC Wainwright set a $10.00 price target on shares of Celldex Therapeutics and gave the company a “buy” rating in a research report on Friday, February 9th. Cantor Fitzgerald restated a “buy” rating and set a $9.00 price target on shares of Celldex Therapeutics in a research report on Wednesday, March 7th. Finally, Leerink Swann restated a “market perform” rating and set a $3.00 price target (down from $4.00) on shares of Celldex Therapeutics in a research report on Thursday, March 8th. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and five have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $6.38.
Celldex Therapeutics (NASDAQ:CLDX) last announced its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.25) by $0.08. Celldex Therapeutics had a negative net margin of 730.06% and a negative return on equity of 44.64%. The company had revenue of $3.50 million during the quarter, compared to analyst estimates of $1.49 million. During the same period in the previous year, the business earned ($0.30) earnings per share. The firm’s quarterly revenue was up 87.2% compared to the same quarter last year. analysts predict that Celldex Therapeutics will post -0.72 EPS for the current fiscal year.
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc, a biopharmaceutical company, focuses on the development and commercialization of various immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer; and CDX-3379, a human monoclonal antibody that is in Phase II study in combination with cetuximab for the treatment of head and neck squamous cell carcinoma.
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.